Human Monoclonal Antibodies Broadly Neutralizing against Influenza B Virus

PLoS Pathogens

Volumn 9, Issue 2, 2013, Pages

  Yasugi, Mayo ^a,b,c   Kubota Koketsu, Ritsuko ^a,c,d   Yamashita, Akifumi ^e   Kawashita, Norihito ^e   Du, Anariwa ^a,c   Sasaki, Tadahiro ^a,c   Nishimura, Mitsuhiro ^a,c   Misaki, Ryo ^c,e   Kuhara, Motoki ^c,f   Boonsathorn, Naphatsawan ^c,g   Fujiyama, Kazuhito ^c,e   Okuno, Yoshinobu ^d   Nakaya, Takaaki ^c,e,h   Ikuta, Kazuyoshi ^a,c  

^a OSAKA UNIVERSITY   (Japan)

^b Osaka Prefecture University   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d Osaka University   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f Medical & Biological Laboratories Co Ltd   (Japan)

^g MINISTRY OF PUBLIC HEALTH   (Thailand)

^h KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY 10C4; HUMAN MONOCLONAL ANTIBODY 3A2; HUMAN MONOCLONAL ANTIBODY 5A7; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUSION; CONTROLLED STUDY; CROSS REACTION; EPITOPE MAPPING; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN CELL; INFLUENZA B; INFLUENZA VIRUS B; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; SURFACE PLASMON RESONANCE; VIRUS LOAD; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BASE SEQUENCE; EPITOPE MAPPING; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; HYBRIDOMAS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NEUTRALIZATION TESTS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 84874787769     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003150     Document Type: Article

References (52)

1. Lambert LC, Fauci AS, (2010) Influenza vaccines for the future. N Engl J Med 363: 2036-2044.
2. WHO (2009) Influenza (Seasonal). Available: http://www.who.int/mediacentre/factsheets/fs211/en/.
3. Carrat F, Flahault A, (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25: 6852-6862.
4. Nobusawa E, Sato K, (2006) Comparison of the mutation rates of human influenza A and B viruses. J Virol 80: 3675-3678.
5. Webster RG, Berton MT, (1981) Analysis of antigenic drift in the haemagglutinin molecule of influenza B virus with monoclonal antibodies. J Gen Virol 54: 243-251.
6. Hay AJ, Gregory V, Douglas AR, Lin YP, (2001) The evolution of human influenza viruses. Philos Trans R Soc Lond B Biol Sci 356: 1861-1870.
7. Lin YP, Gregory V, Bennett M, Hay A, (2004) Recent changes among human influenza viruses. Virus Res 103: 47-52.
8. Sym D, Patel PN, El-Chaar GM, (2009) Seasonal, avian, and novel H1N1 influenza: prevention and treatment modalities. Ann Pharmacother 43: 2001-2011.
9. Belshe RB, (2010) The need for quadrivalent vaccine against seasonal influenza. Vaccine 28 Suppl 4: D45-53.
10. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, et al. (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355: 1845-1850.
11. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, et al. (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51: 123-129.
12. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, et al. (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759-765.
13. Lowen AC, Palese P, (2007) Influenza virus transmission: basic science and implications for the use of antiviral drugs during a pandemic. Infect Disord Drug Targets 7: 318-328.
14. Reece PA, (2007) Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 79: 1577-1586.
15. Suzuki Y, Taira K, Saito R, Nidaira M, Okano S, et al. (2009) Epidemiologic study of influenza infection in Okinawa, Japan, from 2001 to 2007: changing patterns of seasonality and prevalence of amantadine-resistant influenza A virus. J Clin Microbiol 47: 623-629.
16. Jing X, Ma C, Ohigashi Y, Oliveira FA, Jardetzky TS, et al. (2008) Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci U S A 105: 10967-10972.
17. Marasco WA, Sui J, (2007) The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25: 1421-1434.
18. Campas-Moya C, (2010) Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Drugs Today (Barc) 46: 13-22.
19. Cheson BD, (2010) Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 28: 3525-3530.
20. Shirahata S, Katakura Y, Teruya K, (1998) Cell hybridization, hybridomas, and human hybridomas. Methods Cell Biol 57: 111-145.
21. Lonberg N, (2005) Human antibodies from transgenic animals. Nat Biotechnol 23: 1117-1125.
22. Clackson T, Hoogenboom HR, Griffiths AD, Winter G, (1991) Making antibody fragments using phage display libraries. Nature 352: 624-628.
23. McCafferty J, Griffiths AD, Winter G, Chiswell DJ, (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552-554.
24. Jin A, Ozawa T, Tajiri K, Obata T, Kondo S, et al. (2009) A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat Med 15: 1088-1092.
25. Nelson AL, Dhimolea E, Reichert JM, (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9: 767-774.
26. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
27. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
28. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, et al. (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333: 843-850.
29. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
30. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, et al. (2012) Highly conserved protective epitopes on influenza B viruses. Science 337: 1343-1348.
31. Kubota-Koketsu R, Mizuta H, Oshita M, Ideno S, Yunoki M, et al. (2009) Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors. Biochem Biophys Res Commun 387: 180-185.
32. MBL (2010) Press release (Generation of fully human monoclonal antibodies neutralizing influenza virus). Available: http://www.mbl.co.jp/e/ir/2010/0112.html.
33. Setthapramote C, Sasaki T, Puiprom O, Limkittikul K, Pitaksajjakul P, et al. (2012) Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection. Biochem Biophys Res Commun 423: 867-872.
34. Wang Q, Cheng F, Lu M, Tian X, Ma J, (2008) Crystal structure of unliganded influenza B virus hemagglutinin. J Virol 82: 3011-3020.
35. Okuno Y, Isegawa Y, Sasao F, Ueda S, (1993) A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67: 2552-2558.
36. Okuno Y, Matsumoto K, Isegawa Y, Ueda S, (1994) Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 68: 517-520.
37. Knossow M, Gaudier M, Douglas A, Barrere B, Bizebard T, et al. (2002) Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 302: 294-298.
38. Wang TT, Tan GS, Hai R, Pica N, Petersen E, et al. (2010) Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 6: e1000796.
39. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, et al. (2009) Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 5: e1000350.
40. Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, et al. (2011) Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J Virol 85: 8217-8226.
41. Casipit CL, Tal R, Wittman V, Chavaillaz PA, Arbuthnott K, et al. (1998) Improving the binding affinity of an antibody using molecular modeling and site-directed mutagenesis. Protein Sci 7: 1671-1680.
42. Chames P, Coulon S, Baty D, (1998) Improving the affinity and the fine specificity of an anti-cortisol antibody by parsimonious mutagenesis and phage display. J Immunol 161: 5421-5429.
43. Petukhova G, Naikhin A, Chirkova T, Donina S, Korenkov D, et al. (2009) Comparative studies of local antibody and cellular immune responses to influenza infection and vaccination with live attenuated reassortant influenza vaccine (LAIV) utilizing a mouse nasal-associated lymphoid tissue (NALT) separation method. Vaccine 27: 2580-2587.
44. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Sata T, et al. (2001) Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine 19: 1446-1455.
45. Okuno Y, Tanaka K, Baba K, Maeda A, Kunita N, et al. (1990) Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 28: 1308-1313.
46. Chen C, Wang S, Wang H, Mao X, Zhang T, et al. (2012) Potent neutralization of botulinum neurotoxin/b by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain. PLoS One 7: e43845.
47. Gulati U, Hwang CC, Venkatramani L, Gulati S, Stray SJ, et al. (2002) Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J Virol 76: 12274-12280.
48. Ueda M, Daidoji T, Du A, Yang CS, Ibrahim MS, et al. (2010) Highly pathogenic H5N1 avian influenza virus induces extracellular Ca2+ influx, leading to apoptosis in avian cells. J Virol 84: 3068-3078.
49. Katoh K, Misawa K, Kuma K, Miyata T, (2002) MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res 30: 3059-3066.
50. Katoh K, Toh H, (2008) Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform 9: 286-298.
51. Wang Q, Tian X, Chen X, Ma J, (2007) Structural basis for receptor specificity of influenza B virus hemagglutinin. Proc Natl Acad Sci U S A 104: 16874-16879.
52. Ozanne G, (1984) Estimation of endpoints in biological systems. Comput Biol Med 14: 377-384.